45-60% of such patients have coronary vascular dysregulation (endothelial and/or nonendothelial dependent macro-or microvascular dysfunction) capable of causing ischemia with provocative testing. 4, 7 Numerous reports have linked coronary vascular dysregulation, usually referred to as coronary microvascular dysfunction (CMD), with adverse clinical outcomes. [8] [9] [10] But these data have mostly been derived from cohorts of women. Indeed the finding from the NHLBI Women's Ischemic Syndrome Evaluation (WISE) that CMD predicted adverse outcomes 9 has been termed a "milestone" in furthering our understanding of IHD among women. 11 This finding has resulted in multiple attempts to link CMD with female reproductive hormones and other female-specific issues, with variable results.
Yet the role of CMD among men has been open to question since relatively few studies included large numbers of men. In the current issue of Circulation, Murthy et al. report investigations of the prevalence and prognosis of CMD among women and men referred for evaluation of suspected CAD. 12 Patients were assessed with whole-body PET-computed tomography and studies were analyzed semi-quantitatively to identify perfusion defects suggestive of obstructive CAD. PET studies were further processed to determine myocardial blood flow at rest and after stress. Patients without a history of CAD or evidence of a significant perfusion defect at stress (summed stress score <3) were presumed not to have obstructive CAD and were included in the prognosis analysis.
The strengths of this work included a large sample size of both men (n=405) and women (n=813), quantification of CFR, and collection of objective outcomes (cardiac death, myocardial infarction, late revascularization, and heart failure hospitalization) that were adjudicated masked to other findings. Using a CFR<2.0 to define CMD, they found that in both sexes CMD was highly prevalent (>50%) and significantly associated with adverse outcomes. Even in the While the prevalence and associated adverse prognosis of CMD in those patients with a normal perfusion scan included in this cohort is impressive, the true prevalence of CMD is likely to be even higher. Patients with perfusion defects were excluded from the current study, as their perfusion defect was presumed to be caused by obstructive CAD. However, others have shown that 70% of patients with an abnormal myocardial perfusion study but angiographically "normal" epicardial coronaries had CMD. 13 Therefore, some of the patients excluded from this study likely also have had CMD.
The high prevalence of CMD is noteworthy as CMD likely contributes not only to chest discomfort but also to ischemia-related left-ventricular (LV) dysfunction. Diastolic dysfunction is the earliest functional abnormality documented in patients with ischemia secondary to vascular smooth muscle dysfunction (spontaneously occurring coronary spasm). 14 In our studies from the WISE, which included a high prevalence of CMD among women with normal LV systolic function at baseline, a heart failure hospitalization was the most prevalent adverse outcome contributes to the symptoms of patients with heart failure with preserved EF (HFpEF). 15 Similarly, in the Murthy et al. study, patients with a CFR <2.0 were two times more likely to have a heart failure hospitalization versus those with a CFR 2.0. Thus CMD is a potentially important therapeutic target for the growing population of patients with HFpEF.
Because of its high prevalence and associated adverse prognosis, it is important to consider testing for CMD in patients with chest discomfort and/or LV dysfunction of unclear etiology. The investigators used a well-validated method to determine absolute myocardial blood flow reserve with PET. 16, 17 Their study design exemplified the importance of considering absolute and/or regional measures of flow as compared to relative distribution of flow. While a large proportion of patients had documented impairment in CFR, all patients included in the current study had "normal" relative perfusion by PET perfusion imaging. Therefore, when considering a more diffuse process, such as CMD, it is important to use a test that can evaluate absolute myocardial blood flow. In the WISE we performed coronary reactivity testing using a Doppler guide wire in a proximal left coronary. Change in blood flow velocity in response to intra-coronary adenosine is used to determine CFR, and change in coronary flow and coronary cross sectional area in response to intra-coronary acetylcholine are used to define endothelialdependent vascular function. 18 But as most of these patients also have endothelial dysfunction, there is very limited flow-mediated dilation in response to adenosine, so coronary velocity provides a very good estimate of the absolute change in blood flow. 7 In addition to the PET techniques described by these investigators, there are other noninvasive methods available for the evaluation of coronary blood flow and CFR to assess CMD.
Transthoracic Doppler echocardiography provides assessment of coronary blood flow velocity in the left anterior descending (LAD) coronary that can be used to determine CFR after arge proportion of patients had documented impairment in CFR, all patients incl cl lud ud uded ed d i i in n n th th the e e current study had "normal" relative perfusion by PET perfusion imaging. Therefore, when co ons ns nsid id ide er erin in ing g g a a a mo mo ore re re diffuse process, such as CM MD D D, i it is important t to t t u use se e a a a test that can evaluate In conclusion, the present study highlights the importance of considering CMD as an explanation for chest discomfort and/or heart failure among both women and men without flowlimiting epicardial stenoses. In this setting the link between CMD and adverse outcomes appears firmly established. Fortunately, many invasive and non-invasive techniques are available to evaluate coronary microvascular function. The possibility of CMD occurring in the presence of flow-limiting stenoses is also highly likely and warrants additional study relative to its contribution to symptoms and adverse outcomes. Identification of CMD will not only assist in counseling patients on prognosis, but also has the potential to serve as a novel therapeutic target.
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